Cancer “vaccines” enter the neoantigen stage
Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
Few safe havens surface in another down quarter for biopharma
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
Prame looks like the real deal
But can the novel antigen be targeted effectively? Immatics reckons it can, with the right dose and the right manufacturing process.
Esmo 2022 movers – Kras backfires
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
